Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Cuevas, José Manuel ^a,b   Torres Puente, Manuela ^a   Jiménez Hernández, Nuria ^a,b   Bracho, María Alma ^a,b   García Robles, Inmaculada ^a   Wrobel, Boris ^a   Carnicer, Fernando ^c   del Olmo, Juan ^d   Ortega, Enrique ^e   Moya, Andrés ^a,b   González Candelas, Fernando ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A; PROTEIN KINASE R; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVOLUTIONARY ADAPTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; SEQUENCE ALIGNMENT; VIRAL GENETICS; VIRUS GENOME; VIRUS LOAD; COMPLEMENTARITY DETERMINING REGION; DRUG EFFECT; GENETICS; MOLECULAR EVOLUTION; PHYLOGENY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; COMPLEMENTARITY DETERMINING REGIONS; EVOLUTION, MOLECULAR; GENETIC VARIATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; PHYLOGENY; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 52449097214     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003058     Document Type: Article

References (75)

1. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20: 17-35.
2. Pawlotsky JM (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43: S207-S220.
3. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, et al. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695.
4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, et al. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. In International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426-1432.
5. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, et al. (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395-403.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
9. Zeuzem S, Hulcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999.
10. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, et al. (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the Flavivirus envelope and NS1 proteins and the Pestivirus envelope glycoproteins. Virology 180: 842-848.
11. Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Nakazawa T, et al. (1992) Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 22: 107-123.
12. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, et al. (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75: 5703-5710.
13. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, et al. (2000) A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40: 355-366.
14. Troesch M, Meunier I, Lapierre P, Lapointe N, Alvarez F, et al. (2006) Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352: 357-367.
15. Torres-Puente M, Cuevas JM, Jiménez N, Bracho MA, García-Robles I, et al. (2008) Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. Infect Genet Evol 8: 74-82.
16. Duverlie G, Khorsi H, Castelain S, Jaillon O, E Izopet J, et al. (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79:1373-1381.
17. Durante ME, Forton DM, Ruggiero G, Karayiannis P (2003) Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 70: 62-73.
18. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, et al. (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217-227.
19. Gale MJ Jr, Korth MJ, Katze. MG (1998) Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10: 157-162.
20. Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, et al. (1998) Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 72: 6271-6276.
21. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL (1999) Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73: 2938-2946.
22. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, et al. (1997) Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100: 2376-2385.
23. Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, et al. (2001) Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res 52: 153-159.
24. Reed KE, Rice CM (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242: 55-84.
25. Okamoto H, Kurai K, Okada SI, Yamamoto K, Iizuka H, et al. (1992) Fulllength sequence of hepatitis C virus genome having poor homology to reported isolates: Comparative studiy of four distinct genotypes. J Gen Virol 188: 331-341.
26. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, et al. (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288: 339-344.
27. Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, et al. (2002) Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 83: 11-23.
28. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, et al. (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 99: 3081-3086.
29. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl J Med 334: 77-81.
30. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, et al. (1997) Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25: 745-749.
31. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. (1992) Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 89: 3468-3472.
32. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, et al. (1993) Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67: 3923-3930.
33. Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, et al. (1993) A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195: 297-301.
34. Farci P, Purcell RH (2000) Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20: 103-126.
35. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, et al. (2005) Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 86: 1067-1075.
36. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, et al. (2005) Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79: 3071-3083.
37. Torres-Puente M, Cuevas JM, Jiménez N, Bracho MA, Garcia-Robles I, et al. (2008) Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Vir Hepat 15: 188-199.
38. Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, Bracho MaA, Garcia-Robles I, et al. (2008) Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response. J Vir Hepat 15: 578-590.
39. Ciccaglione AR, Marcantonio C, Equestre M, Jones IM, Rapicetta M (1998) Secretion and purification of HCV E1 protein forms as glutathione-S-transferase fusion in the baculovirus insect cell system. Virus Res 55: 157-165.
40. Cocquerel L, Duvet S, Meunier JC, Pillez A, Cacan R, et al. (1999) The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J Virol 73: 2641-2649.
41. Dubuisson J (2000) Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 242: 135-148.
42. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73: 6235-6244.
43. Lee JW, Kim K, Jung SH, Lee KJ, Choi EC, et al. (1999) Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol 73: 11-18.
44. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
45. Layden-Almer JE, Kuiken C, Ribeiro RM, Kunstman KJ, Perelson AS, et al. (2005) Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 192: 1078-1087.
46. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM (1991) Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A 88: 10292-10296.
47. Nousbaum JB, Polyak SJ, Ray SC, Sullivan DG, Larson AM, et al. (2000) Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74: 9028-9038.
48. Herion D, Hoofnagle JH (1997) The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 25: 769-771.
49. Lusida MI, Nagano-Fujii M, Nidom CA, Soetjipto, Handajani R, et al. (2001) Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol 39: 3858-3864.
50. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, et al. (2004) Sustained virological response in hepatitis C virus type 1b, infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53: 1345-1351.
51. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, Bracho MA, Garcia-Robles I, et al. (2008) Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment. J Med Virol 80: 247-253.
52. Maynard-Smith JM, Haigh J (1974) The hitch-hiking effect of a favourable gene. Genet Res 23: 23-35.
53. Charlesworth B, Morgan MT, Charlesworth D (1993) The effect of deleterious mutations on neutral molecular variation. Genetics 134: 1289-1303.
54. Cuevas JM, Elena SF, Moya A (2002) Molecular basis of adaptive convergence in experimental populations of RNA viruses. Genetics 162: 533-542.
55. Lau JYN, Tam RC, Liang TJ, Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009.
56. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, et al. (2007) Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-a against hepatitis C virus. J Infect Dis 196: 425-434.
57. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98: 6895-6900.
58. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100: 7289-7294.
59. Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, et al. (2007) Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterol 132: 921-930.
60. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM (2007) Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 81: 7732-7741.
61. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, et al. (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38: 869-878.
62. Kuiken C, Combet C, Bukh J, Shin-i T, Deleage G, et al. (2006) A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44: 1355-1361.
63. Jimenez-Hernandez N, Torres-Puente M, Bracho MA, Garcia-Robles I, Ortega E, et al. (2007) Epidemic dynamics of two coexisting hepatitis C virus subtypes. J Gen Virol 88: 123-133.
64. Bracho MA, García-Robles I, Jiménez N, Torres-Puente M, Moya A, González-Candelas F (2004) Effect of oligonucleotide primers in determining viral variability within hosts. Virol J 1: 13.
65. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res 25: 4876-4882.
66. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R (2003) DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19: 2496-2497.
67. Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated Software for Molecular Evolutionary Genetics Analysis and Sequence Alignment. Brief Bioinform 5: 150-163.
68. Korber B, Myers G (1992) Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retrovir 8: 1549-1560.
69. Yang Z, Nielsen R, Goldman N, Pedersen AMK (2000) Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431-449.
70. Yang Z (1997) PAML: a program package for phylogenetic analysis by maximum likelihood. CABIOS 13: 555-556.
71. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19: 716-723.
72. Yang Z, Wong WSW, Nielsen R (2005) Bayes empirical Bayes inference of amino acid sites under positive selection. Mol Biol Evol 22: 1107-1118.
73. Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696-704.
74. Feinstone SM, Alter HJ, Dienes HP, Shimizu Y, Popper H, et al. (1981) Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 144: 588-598.
75. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, et al. (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 87: 9524-9528.